ATE267013T1 - Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit - Google Patents
Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeitInfo
- Publication number
- ATE267013T1 ATE267013T1 AT01910051T AT01910051T ATE267013T1 AT E267013 T1 ATE267013 T1 AT E267013T1 AT 01910051 T AT01910051 T AT 01910051T AT 01910051 T AT01910051 T AT 01910051T AT E267013 T1 ATE267013 T1 AT E267013T1
- Authority
- AT
- Austria
- Prior art keywords
- metabotropic
- glutama
- dependency
- receptor antagonists
- tolerance
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000001613 Gambling Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fertilizers (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0005700.0A GB0005700D0 (en) | 2000-03-09 | 2000-03-09 | Therapy |
| PCT/GB2001/001058 WO2001066113A1 (en) | 2000-03-09 | 2001-03-09 | Metabotropic glutamate receptor antagonists for treating tolerance and dependency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE267013T1 true ATE267013T1 (de) | 2004-06-15 |
Family
ID=9887294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01910051T ATE267013T1 (de) | 2000-03-09 | 2001-03-09 | Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20030195139A1 (https=) |
| EP (1) | EP1267869B1 (https=) |
| JP (1) | JP2003525902A (https=) |
| CN (1) | CN1427720A (https=) |
| AT (1) | ATE267013T1 (https=) |
| AU (1) | AU783869B2 (https=) |
| CA (1) | CA2402341A1 (https=) |
| DE (1) | DE60103384T2 (https=) |
| DK (1) | DK1267869T3 (https=) |
| ES (1) | ES2220727T3 (https=) |
| GB (1) | GB0005700D0 (https=) |
| NZ (1) | NZ521228A (https=) |
| PT (1) | PT1267869E (https=) |
| SE (1) | SE1267869T5 (https=) |
| TR (1) | TR200401862T4 (https=) |
| WO (1) | WO2001066113A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0314192A (pt) | 2002-09-10 | 2005-07-26 | Novartis Ag | Antagonistas de receptores de mglu para tratamento de distúrbios associados com receptores de mglu incluindo vìcio e depressão |
| US8778979B2 (en) | 2005-04-05 | 2014-07-15 | Yale University | Glutamate agents in the treatment of mental disorders |
| US20060264381A1 (en) * | 2005-05-05 | 2006-11-23 | Bear Mark F | Methods of treating obsessive compulsive disorder |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US7531541B2 (en) * | 2005-09-20 | 2009-05-12 | Vanderbilt University | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| DE102005062985A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| ES2610508T3 (es) | 2006-11-22 | 2017-04-27 | Clinical Research Associates, Llc | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012054724A1 (en) | 2010-10-21 | 2012-04-26 | Massachusetts Institute Of Technology | Methods of treating seizure disorders |
| US20130123254A1 (en) * | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| GB201312800D0 (en) | 2013-07-17 | 2013-08-28 | Heptares Therapeutics Ltd | mGlu5 modulators |
| CA3066711A1 (en) * | 2017-07-31 | 2019-02-07 | Novartis Ag | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
| CA3067688A1 (en) | 2017-07-31 | 2019-02-07 | Novartis Ag | Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use |
| MX2023000664A (es) * | 2020-07-17 | 2023-02-27 | Novartis Ag | Uso de antagonistas de mglur5. |
| AU2021404023A1 (en) * | 2020-12-14 | 2023-06-29 | Novartis Ag | Use of mglur5 antagonists for treating gambling disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| US5543698A (en) * | 1994-09-27 | 1996-08-06 | Allen-Bradley Company, Inc. | Method and apparatus used with AC motor for detecting unbalance |
| GB9609976D0 (en) * | 1996-05-13 | 1996-07-17 | Lilly Industries Ltd | Pharmaceutical compounds |
| CA2287591A1 (en) * | 1997-03-14 | 1998-09-17 | The Johns Hopkins University School Of Medicine | Synaptic activation protein compositions and method |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6057368A (en) * | 1998-08-05 | 2000-05-02 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
| EP1117403B1 (en) * | 1998-10-02 | 2003-12-10 | Novartis AG | Mglur5 antagonists for the treatment of pain and anxiety |
| TW593241B (en) * | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
| EP1183238A1 (en) * | 1999-05-17 | 2002-03-06 | Eli Lilly And Company | Metabotropic glutamate receptor antagonists |
| US6666209B2 (en) * | 2001-02-20 | 2003-12-23 | 3M Innovative Properties Company | Method and system of calibrating air flow in a respirator system |
-
2000
- 2000-03-09 GB GBGB0005700.0A patent/GB0005700D0/en not_active Ceased
-
2001
- 2001-03-09 AU AU37634/01A patent/AU783869B2/en not_active Ceased
- 2001-03-09 PT PT01910051T patent/PT1267869E/pt unknown
- 2001-03-09 AT AT01910051T patent/ATE267013T1/de not_active IP Right Cessation
- 2001-03-09 DK DK01910051T patent/DK1267869T3/da active
- 2001-03-09 TR TR2004/01862T patent/TR200401862T4/xx unknown
- 2001-03-09 CN CN01808891A patent/CN1427720A/zh active Pending
- 2001-03-09 US US10/221,128 patent/US20030195139A1/en not_active Abandoned
- 2001-03-09 WO PCT/GB2001/001058 patent/WO2001066113A1/en not_active Ceased
- 2001-03-09 EP EP01910051A patent/EP1267869B1/en not_active Revoked
- 2001-03-09 CA CA002402341A patent/CA2402341A1/en not_active Abandoned
- 2001-03-09 DE DE60103384T patent/DE60103384T2/de not_active Revoked
- 2001-03-09 SE SE01910051T patent/SE1267869T5/xx unknown
- 2001-03-09 NZ NZ521228A patent/NZ521228A/en unknown
- 2001-03-09 ES ES01910051T patent/ES2220727T3/es not_active Expired - Lifetime
- 2001-03-09 JP JP2001564765A patent/JP2003525902A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE60103384D1 (de) | 2004-06-24 |
| AU3763401A (en) | 2001-09-17 |
| SE1267869T5 (https=) | 2004-09-07 |
| DK1267869T3 (da) | 2004-09-20 |
| EP1267869B1 (en) | 2004-05-19 |
| WO2001066113A1 (en) | 2001-09-13 |
| CN1427720A (zh) | 2003-07-02 |
| NZ521228A (en) | 2004-04-30 |
| EP1267869A1 (en) | 2003-01-02 |
| AU783869B2 (en) | 2005-12-15 |
| ES2220727T3 (es) | 2004-12-16 |
| HK1053262A1 (en) | 2003-10-17 |
| SE1267869T3 (https=) | 2004-08-31 |
| TR200401862T4 (tr) | 2004-10-21 |
| CA2402341A1 (en) | 2001-09-13 |
| DE60103384T2 (de) | 2005-06-16 |
| GB0005700D0 (en) | 2000-05-03 |
| JP2003525902A (ja) | 2003-09-02 |
| US20030195139A1 (en) | 2003-10-16 |
| PT1267869E (pt) | 2004-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE267013T1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit | |
| DE69726724D1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
| ATE313326T1 (de) | VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß | |
| DE60022692D1 (de) | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen | |
| DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
| ATE255894T1 (de) | Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen | |
| BRPI0418112A (pt) | inibidores de p-38 quinase bicìclico heterocìclicos | |
| ES2194960T3 (es) | N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f. | |
| BRPI0413022A (pt) | derivados de 3-amino cromado e 2-amino tetralina | |
| DE60206164D1 (de) | Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1-naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren | |
| DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| DE69524623D1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| ATE290862T1 (de) | Anti-androgene und verfahren zur behandlung von krankheiten | |
| DE60218153D1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
| DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| ATE320832T1 (de) | Behandlung von haarfollikeln mit neurokinin 1 rezeptor antagonisten | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| DE69827387D1 (de) | Verwendung von pramipexol zur behandlung von restless-legs-syndrom | |
| DK0422154T3 (da) | Terapeutisk anvendelse af 5-HT3-receptorantagonister | |
| DE60209886D1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
| DE60117541D1 (de) | Candesartan zur Behandlung von Migräne | |
| ATE291425T1 (de) | R-eliprodil zur behandlung von glaucoma | |
| ATE360425T1 (de) | Verwendung von quetiapin für die behandlung von kokain-abhängigkeit | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1267869 Country of ref document: EP |
|
| RZN | Patent revoked |